One important requirement for the recognition and killing of cancer cells by specialized cells of the immune system, such as cytotoxic CD8+ T lymphocytes (CTL), is the presentation of tumor-specific peptides by major histocompatibility complex (MHC; also human leukocyte antigen (HLA)) molecules on the cell surfaces of the cancer cells. Here, CD8A is linked to neoplasm.